Pharmaceutical Business review -

Pharmaceutical Business review is using cookies

Continue Learn More

Close

November 14, 2018

AbbVie’s Mavyret shows high virologic cure rates in HCV study

AbbVie’s Mavyret (glecaprevir/pibrentasvir) has showed high virologic cure rates in treatment-naïve patients with compensated cirrhosis in the phase 3b Expedition-8 study.

Image: AbbVie US headquarters. Photo: courtesy of AbbVie Inc.

November 14, 2018

FDA grants priority review to Tecentriq combo for triple-negative breast cancer

Image: Roche’s Tecentriq gets FDA priority review for triple-negative breast cancer. Photo: courtesy of F. Hoffmann-La Roche Ltd.

November 13, 2018

Lynparza maintenance therapy secures FDA priority review for ovarian cancer

Image: Lynparza tablets. Photo: courtesy of AstraZeneca.

Contracts

October 8, 2018

hVIVO signs new contracts with global biopharmaceutical firm

Image: hVIVO has signed new contracts with global biopharmaceutical firm. Photo: courtesy of rawpixel / Unsplash.

Opiant signs contract with BARDA to accelerate OPTN003 product development

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Drug Manufacturing

Data science company IXICO extends contract with biopharmaceutical firm

Deals

Deals November 9, 2018

BioTime signs merger deal with Asterias Biotherapeutics

Pharmaceutical Business Review

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

Alexion wraps up $1.2bn acquisition of Syntimmune

Popular

Videos

Suppliers

Spotlight

Pharmaceutical Business Review

BMS, Infinity to assess Opdivo-IPI-549 combo in urothelial cancer

Pharmaceutical Business Review

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

Pharmaceutical Business Review

Arrowhead, Janssen sign $3.7bn license and collaboration deal